Jiun Chyun June revenue change -1.23%

Jiun Chyun June revenue change -1.23%

Canopy Growth Corporation (CGC) ended the recent trading session at $1.23, marking a +2.5% change from the previous day's closing price. This performance outpaced the S&P 500's daily loss of 0.07%, with the Dow losing 0.37% and the tech-heavy Nasdaq adding 0.03%. Over the past month, Canopy Growth Corporation shares have lost 25.93%, lagging the Medical sector's loss of 1.3% and the S&P 500's gain of 3.94% [1].

Investors are eagerly anticipating Canopy Growth Corporation's upcoming earnings disclosure. The company is expected to report earnings per share (EPS) of -$0.11, an increase of 70.27% from the prior-year quarter. Additionally, revenue is projected to be $48.08 million, a 0.64% drop compared to the year-ago quarter. For the full year, Zacks Consensus Estimates project earnings of -$0.43 per share and revenue of $199.33 million, representing changes of +85.57% and +3.12%, respectively, from the prior year [1].

The Zacks Rank, a system that capitalizes on estimate revisions, currently ranks Canopy Growth Corporation at #3 (Hold). The Medical - Products industry, part of the Medical sector, holds a Zacks Industry Rank of 89, positioning it in the top 37% of all 250+ industries [1].

In contrast, RxSight Inc. (RXST) reported preliminary Q2 2025 revenue expected to be down 4% year-over-year, missing analyst expectations. The company revised its 2025 revenue guidance downward to $120 million-$130 million, from $160 million-$175 million, and increased its 2025 gross margin guidance to 72%-74%, up from 71%-73% [2].

References:
[1] https://finance.yahoo.com/news/canopy-growth-corporation-cgc-increases-220005765.html
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_PLXE27FE3:0-rxsight-expects-preliminary-q2-revenue-down-4/